Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.

Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their […]

A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.

Although SXSW 2016 lacked a major platform launch, it did further the tech discussion in key areas.